Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on ArriVent BioPharma, Inc. and keeping the price target at $42.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sam Slutsky has given his Buy rating due to a combination of factors, including supportive external validation for the Firmonertinib program and encouraging early efficacy data. The recent positive Phase 3 sunvozertinib result in first-line EGFR exon 20 insertion NSCLC versus chemotherapy reinforces the therapeutic relevance of this target class and strengthens confidence that ArriVent’s FURVENT Phase 3 trial could achieve a similar outcome.
In addition, Firmonertinib’s prior Phase 1b data show a high objective response rate and prolonged duration of response relative to historical benchmarks such as mobocertinib and amivantamab plus chemotherapy, despite cross-trial comparison caveats. The drug’s CNS penetrance and potentially cleaner tolerability profile versus sunvozertinib provide further differentiation, supporting the unchanged $42 price target and the view that AVBP shares offer attractive upside if Phase 3 results are successful.
In another report released on April 24, Citi also assigned a Buy rating to the stock with a $45.00 price target.